FDA Clears Adjunctive AI for Non-Contrast CT of Brain Injuries and Hemorrhages
RapidAI’s Rapid Hyperdensity tool reportedly allows quicker assessment of hyperdense tissue in the brain via non-contrast computed tomography (CT) scans.
RapidAI has received FDA 510(k) clearance for Rapid Hyperdensity, an artificial intelligence (AI)-enabled tool that may allow for more timely assessment of traumatic brain injuries and hemorrhages.
Rapid Hyperdensity’s AI-powered review of non-contrast computed tomography (CT) enables radiologists to quickly determine the extent of hyperdense tissue volume associated with acute neurological conditions such as intracerebral hemorrhage (ICH), according to RapidAI.
Alejandro M. Spiotta, M.D., said the automated detection of intracranial hyperdense tissue volume with Rapid Hyperdensity is a significant advance in facilitating timely triage and ongoing assessment of patients with ICH.
“Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient,” noted Dr. Spiotta, the director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
